Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 3/20 | 0.35 |
| ▸ | F13A1 | P00488 | 2/20 | 0.35 |
| ▸ | TGM1 | P22735 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16117973 | 0.90 | NR1H2 (0.42) | KRASNR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL16094196 | 0.84 | SETD7 (0.38) | KRASNR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL16093824 | 0.81 | KRAS (0.38) | KRASTGM2F13A1TGM1USP2 | |
| SCHEMBL16121827 | 0.78 | USP2 (0.44) | KRASNR1H2TGM2F13A1TGM1 | |
| SCHEMBL21302139 | 0.75 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16099877 | 0.75 | NR1H2 (0.42) | KRASNR1H2MEN1ALDH1A1MAPT | |
| SCHEMBL24449830 | 0.74 | PARP1 (0.50) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20208672 | 0.74 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20208681 | 0.74 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3356491 | 0.73 | USP2 (0.55) | MEN1KMT2ATGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885NR1H2 3774/4885MEN1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.